What is the mechanism of action of dacomitinib/dacomitinib? How does it work?

Dacomitinib is a kinase inhibitor for epidermal growth factor receptor (EGFR pan>) First-line treatment of patients with metastatic non-small cell lung cancer who have exon 19 deletions or exon 21 substitution mutations.

Dacomitinib/Dacomitinib is a member of the human EGFR family (EGFR/HER1, HER2 span> and HER4) and certain EGFR activating mutations (exon 19 deletion or exon 21 L858R substitution mutation) irreversible inhibitor of kinase activity. At clinically relevant concentrations, dacomitinib/dacomitinib also inhibits DDR1, EPH in vitro Activities of A6, LCK, DDR2 and MNK1. Dacomitinib/Dacomitinibproves EGFR and HER2Dose-dependent inhibition of autophosphorylation and tumor growth in mice implanted subcutaneously with human tumor xenografts driven by HER family targets including mutant EGFR. Dacotinib also demonstrated antitumor activity in orally administered mice bearing intracranial human tumor xenografts driven by EGFR amplification. The average absolute bioavailability of dacomitinib after oral administration is 80%. Dacomitinib/DacomitinibThe median time to maximum concentration (Tmax) occurs in cancer patients after a single oral doseVIZIMPRO 45 mgabout 6.0 hours (2.0 to 24 hours). Consume a high-fat, high-calorie meal (approximately 800 to 1,000 calories, 150, 250, and calories from protein, carbohydrates, and fat, respectively. VIZIMPRO had no clinically meaningful effect on the pharmacokinetics of dacomitinib/dacomitinib. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.

xa0